H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 60 from EUR 34 and keeps a Buy rating on the shares after the company presented updated efficacy results from Part 1 of the open-label Phase 2 CONVERGE study evaluating JNJ-1900 as an enhancer to radiotherapy in patients with stage 3 inoperable non-small cell lung cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix Fast-Tracks Pivotal Head and Neck Cancer Trial with FDA-Backed Protocol Shift
- Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment
- Nanobiotix price target raised to $30 from $3.50 at UBS
- Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating
- Nanobiotix Unveils Preclinical Data Showing Nanoprimer Boosts LNP-DNA Cancer Immunotherapy